Bibliography
- LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353:1209-1223.
- MELTZER HY, BOBO WV: Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS spectr. (2006) 11:14-24.
- SODERLING SH, BEAVO JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. (2000) 12:174-179.
- BENDER AT, BEAVO JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. (2006) 58:488-520.
- BEAVO JA, HOUSLAY MD, FRANCIS SH: Cyclic nucleotide phosphodiesterase superfamily. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH, Houslay MD (Eds), CRC Press, Boca Raton (2007):3-17.
- SODERLING SH, BAYUGA SJ, BEAVO JA: Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA (1999) 96:7071-7076.
- LOUGHNEY K, SNYDER PB, UHER L, ROSMAN GJ, FERGUSON K, FLORIO VA: Isolation and characterization of PDE10A, a novel human 3´5´-cyclic nucleotide phosphodiesterase. Gene (1999) 234:109-117.
- FUJISHIGE K, KOTERA J, MICHIBATA H et al.: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. (1999) 274:18438-18445.
- STROOP SD, CHARBONNEAU H, BEAVO JA: Direct photolabeling of the cGMP-stimulated cyclic nucleotide phosphodiesterase. J. Biol. Chem. (1989) 15:13718-13725.
- MCALLISTER-LUCAS LM, HAIK TL, COLBRAN JL et al.: An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J. Biol. Chem. (1995) 270:30671-30679.
- GILLESPIE PG, BEAVO JA: cGMP is tightly bound to bovine retinal rod phosphodiesterase. Proc. Natl. Acad. Sci. USA (1989) 86:4311-4315.
- GROSS-LANGENHOFF M, HOFBAUER K, WEBER J, SCHULTZ A, SCHULTZ JE: cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J. Biol. Chem. (2006) 281:2841-2846.
- FUJISHIGE K, KOTERA J, OMORI K: Striatum- and testis-specific phosphodiesterase PDE10A. Isolation and characterization of a rat PDE10A. Eur. J. Biochem. (1999) 266:1118-1127.
- KOTERA J, FUJISHIGE K, YUASA K, OMORI K: Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP. Biochem. Biophys. Res. Commun. (1999) 261:551-557.
- O’CONNOR V, GENIN A, DAVIS S et al.:Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific PDE10A phosphodiesterase splice variants. J. Biol. Chem. (2004) 279:15841-15849.
- KOTERA J, SASAKI T, KOBAYASHI T, FUJISHIGE K, YAMASHITA Y, OMORI K: Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J. Biol. Chem. (2004) 279:4366-4375.
- SEEGER TF, BARTLETT B, COSKRAN TM et al.: Immunohistochemical localization of PDE10A in the rat brain. Brain Res. (2003) 985:113-126.
- XIE Z, ADAMOWICZ WO, ELDRED WD et al.: Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience (2006) 139:597-607.
- COSKRAN TM, MORTON D, MENNITI FS et al.: Immunohistochemical localizationof phosphodiesterase PDE10A in multiple mammalian species. J. Histochem. Cytochem. (2006) 54:1205-1213.
- RING HA, SERRA-MESTRES J: Neuropsychiatry of the basal ganglia. J. Neurol. Neurosurg. Psychiatry (2002) 72:12-21.
- GRAYBIEL AM: The basal ganglia. Curr. Biol. (2000) 10:R509-R511.
- SIUCIAK JA, MCCARTHY SA, CHAPIN DS et al.: Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology (2006) 51:374-385.
- SIUCIAK JA, CHAPIN DS, HARMS JF et al.: Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology (2006) 51:386-396.
- MERCK GM: Vorläufige Notiz über eine neue organische Base im Opium. Ann. (1848) 66:125-128.
- PICTET A, GAMS A: Comptes rendus hebdomadaires des séances de l’Académie des sciences (1909) 149:210-212.
- SCHIFF PL: Opium and its alkaloids. Am. J. Pharm. Educ. (2002) 66:186-194.
- CHAPPIE TA, HUMPHREY JM, ALLEN MP et al.: Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J. Med. Chem. (2007) 50:182-185.
- SIUCIAK JA, CHAPIN DS, MCCARTHY SA et al.: Novel potent and selective phosphodiesterase 10A (PDE10A) inhibitors show activity in animal models of psychosis. Neuroscience Meeting Planner, Society for Neuroscience (2006).
- SIUCIAK JA, CHAPIN DS, MCCARTHY SA et al.: Novel potent and selective PDE10A inhibitors show activity in animal models of psychosis and anxiety. Schizophrenia Bulletin (2007) 33:479.
- JAMES LC, FOX CB, CHAPPIE T et al.: Induction of striatal gene expression by PDE10A inhibitors. Neuroscience Meeting Planner, Society for Neuroscience (2006).
- LINDHOLM E, EKHOLM B, SHAW S et al.: A schizophrenia-susceptibility locus at 6q25, in one of the world’s largest reported pedigrees. Am. J. Hum. Genet. (2001) 69:96-105.
- KAPUR S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry (2003) 160:13-23.
- WADENBERG ML, HICKS PB: The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci. Biobehav. Rev. (1999) 23:851-862.
- TAMMINGA CA: The neurobiology of cognition in schizophrenia. Schizo cog review. J. Clin. Psychiatry (2006) 67:9-13.
- FUJII DE, WYLIE AM: Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr. Res. (2003) 59:219-223.
- RODEFER JS, MURPHY ER, BAXTER MG: PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. J. Neurosci. (2005) 21:1070-1076.
- JENTSCH JD, ROTH RH: The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology (1999) 20:201-225.
- LIU F, ZHANG G, KELLEY C, DAY M, MARQUIS K, BRANDON N: Biochemical analysis of mechanism action of PDE10A inhibitor papaverine in pro-cognitive effects. Neuroscience Meeting Planner, Society for Neuroscience (2006).
- NEWCOMER JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J. Clin. Psychiatry (2007) 68:20-27.
- KELLEY AE: Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci. Biobehav. Rev. (2004) 27:765-776.
- BLACK SC, GIBBS M, MCNEISH JD et al.: Genetic deletion of phosphodiesterase 10A results in a phenotype of resistance to high fat diet-induced obesity, elevated circulating adiponectin and improved glucose tolerance: a new drug target. Keystone Symposium Abstracts, Adipogenesis, Obesity and Inflammation (2006):149.
- POLLI JW, KINCAID RL: Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc. Natl. Acad. Sci. USA (1992) 89:11079-11083.
- YAN C, BENTLEY JK, SONNENBURG WK, BEAVO JA: Differential expression of the 61 kDa and 63 kDa calmodulin-dependent phosphodiesterases in the mouse brain. J. Neurosci. (1994) 14:973-984.
- VAN STAVEREN WC, STEINBUSCH HW, MARKERINK-VAN ITTERSUM M et al.: mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J. Comp. Neurol. (2003) 467:566-580.
- JUILFS DM, SODERLING S, BURNS F, BEAVO JA: Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs). Rev. Physiol. Biochem. (1999) 135:67-104.
- CHERRY JA, DAVIS RL: Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. (1999) 407:287-301.
- CHO CH, CHO DH, SEO MR, JUHNN YS: Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp. Mol. Med. (2000) 32:110-114.
- SASAKI T, KOTERA J, OMORI K: Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem. J. (2002) 361:211-220.
- REYES-IRISARRI E, PEREZ-TORRES S, MENGOD G: Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience (2005) 132:1173-1185.
- KANES SJ, TOKARCZYK J, SIEGEL SJ, BILKER W, ABEL T, KELLY MP: Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience (2007) 144:239-246.
- DAVIS JA, GOULD TJ: Rolipram attenuates MK-801-induced deficits in latent inhibition. Behav. Neurosci. (2005) 119:595-602.
- MORI T, BABA J, ICHIMARU Y, SUZUKI T: Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice. Jpn. J. Pharmacol. (2000) 83:113-118.
- SIUCIAK JA, CHAPIN DS, MCCARTHY SA, MARTIN AN: Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (2007) 192:415-424.
- CHAPIN DS, MCCARTHY SA, MARTIN AN, SIUCIAK JA: Rolipram, a PDE4 inhibitor, shows efficacy in animal models of antipsychotic-like activity: studies using PDE4B and PDE4D knockout mice. Schizophrenia Bulletin (2007) 33:470.
- ROSE GM, HOPPER A, DE VIVO M, TEHIM A: Phosphodiesterase inhibitors for cognitive enhancement. Curr. Pharm. Des. (2005) 11:3329-3334.
- PIETZCKER A, MULLER-OERLINGHAUSEN B, KEHR W: Antipsychotic activity of rolipram in schizophrenic patients. A pilot study. Naunyn-Schmiedebergs Arch. Pharmacol. (1979) 308:R44.
- MIRO X, PEREZ-TORRES S, PUIGDOMENECH P, PALACIOS JM, MENGOD G: Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse (2002) 45:259-269.
- REED TM, BROWNING JE, BLOUGH RI, VORHEES CV, REPASKE DR: Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene. Mamm. Genome (1998) 9:571-576.
- SIUCIAK JA, MCCARTHY SA, CHAPIN DS, REED TM, VORHEES CV, REPASKE DR: Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology (2007) [Epub ahead of print].
- EHRMAN LA, WILLIAMS MT, SCHAEFER TL et al.: Phosphodiesterase 1B differentially modulates the effects of methamphetamineon locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav. (2006) 5:540-551.
- MELONE MAB, JORI FP, PELUSO G: Huntington’s disease: new frontiers for molecular and cell therapy. Curr. Drug Targets (2005) 6:43-56.
- HEBB ALO, ROBERTSON HA, DENOVAN-WRIGHT EM: Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington’s disease transgenic mice prior to the onset of motor symptoms. Neuroscience (2004) 123:967-981.
- HU H, MCCAW EA, HEBB ALO, GOMEZ GT, DENOVAN-WRIGHT EM: Mutant huntintin affects the rat of transcription of striatum-specificisoforms of phophodiesterase 10A. Eur. J. Neurosci. (2004) 20:3351-3363.